Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug interactions with valproic acid.

R H Levy, K M Koch

    Drugs
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Valproic acid frequently interacts with other anticonvulsants, affecting drug efficacy and requiring dose adjustments. These interactions, involving metabolism changes and protein binding, have significant clinical implications for patient treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quantitative Susceptibility Mapping after Sports-Related Concussion.

    AJNR. American journal of neuroradiology·2018
    Same author

    The multi-millennial Antarctic commitment to future sea-level rise.

    Nature·2015
    Same author

    Antarctic contribution to meltwater pulse 1A from reduced Southern Ocean overturning.

    Nature communications·2014
    Same author

    Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.

    European journal of cancer (Oxford, England : 1990)·2012
    Same author

    Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

    Neurology·2012
    Same journal

    Ecnoglutide: First Approvals.

    Drugs·2026
    Same journal

    The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

    Drugs·2026
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Drug Interactions

    Background:

    • Valproic acid is widely prescribed for various indications, often alongside other anticonvulsant medications.
    • Concomitant use of valproic acid with other anticonvulsants frequently leads to drug-drug interactions.
    • These interactions are often reciprocal and can significantly impact therapeutic outcomes.

    Purpose of the Study:

    • To review the pharmacokinetic and pharmacodynamic interactions of valproic acid with commonly used anticonvulsants.
    • To elucidate the mechanisms underlying these drug-drug interactions.
    • To highlight the clinical significance of these interactions in patient management.

    Main Methods:

    • Literature review of studies investigating valproic acid interactions.

    Related Experiment Videos

  • Analysis of pharmacokinetic data related to protein binding displacement and metabolic inhibition.
  • Examination of clinical consequences of identified interactions.

    • Main Results:

    • Valproic acid acts as a protein binding displacer and metabolic inhibitor for several anticonvulsants (e.g., phenobarbitone, primidone, phenytoin).
    • Metabolic inhibition by valproic acid can decrease the required dosage of interacting anticonvulsants.
    • Valproic acid's metabolism is inducible by anticonvulsants like carbamazepine and phenytoin, potentially altering valproic acid levels.
    • Valproic acid is highly protein-bound, making it susceptible to displacement by substances like salicylates and free fatty acids, though this may not alter its dose-response relationship.

    Conclusions:

    • Valproic acid exhibits significant drug-drug interactions with numerous anticonvulsants.
    • Understanding these interactions is crucial for optimizing anticonvulsant therapy and preventing adverse events.
    • Monitoring and dose adjustments are often necessary when valproic acid is co-administered with other anticonvulsants.